---
title: 癌症疫苗终于显现出希望。
date: 2024-05-23T04:00:37.121Z
description: As Covid revenues slump, technology developed to fight the pandemic is having some success combating this disease
tag: 

- Tag companies
author: ft
---

[原文链接](https://ft.com/content/d1d3c6b0-307a-485b-a48b-be635cdfd243)

癌症疫苗终于显现出希望。

## 新冠疫苗技术的进步给癌症研究带来了希望

这篇文章讨论了**癌症疫苗技术**方面的一些令人振奋的进展，尤其关注由 Moderna 和 BioNTech 开发的基于 mRNA 的免疫疗法。这些公司正在利用他们从新冠疫苗中获得的经验来对抗各种类型的癌症。目前，针对黑色素瘤的全球首个个性化 mRNA 癌症免疫疗法正处于第三阶段临床试验，如果成功，预计每年可达到**10亿美元**的峰值销售额。其他公司，如牛津和默克，也正在探索预防肺癌和与 HPV 相关的癌症的疫苗。

### 一些有趣的问题：
**Dendreon 在开发其前列腺癌疫苗时面临着怎样的挑战？当前 mRNA 免疫疗法开发者们是如何解决这些问题的?**
Dendreon 面临生产成本高和成本效益受到质疑等重大障碍。当前 mRNA 免疫疗法的研发人员正在瞄准、输送和组合治疗方面取得进步，以克服这些挑战。通过提高技术的效率和有效性，他们旨在开发出更经济实惠、更易获得的癌症治疗方法。

**Moderna 的黑色素瘤 mRNA 免疫疗法成功会对其他类型的癌症产生什么影响?**
如果 Moderna 的 mRNA 免疫疗法取得成功，可能会为开发和测试针对各种癌症类型的类似疗法铺平道路。这将扩大其潜在市场价值，并为不同类型癌症的患者提供更多治疗选择。此外，它还可能鼓励进一步研究个性化医疗方法，以适应个人肿瘤基因特征。

**决定 mRNA 免疫疗法公司（如 Moderna 和 BioNTech）估值的有哪些因素?**
mRNA 免疫疗法公司的估值受到多个因素的影响，包括疫苗和治疗管线、每个产品的潜在市场规模、临床试验结果、知识产权（例如专利），以及竞争格局。在评估公司价值时，投资者还会考虑该公司的财务状况、管理团队和战略合作伙伴关系。在这个快速发展的领域中，关键产品的成败可能会显著影响公司的估值。

---

## Summary:
The article discusses the promising advancements in cancer vaccine technology, particularly focusing on mRNA-based immunotherapies developed by Moderna and BioNTech. These companies are leveraging their experience from Covid-19 vaccines to combat various types of cancers. The world's first personalized mRNA cancer immunotherapy for melanoma is currently in phase 3 clinical trials, with potential peak annual sales reaching $1 billion if successful. Other companies like Oxford and Merck are also exploring prophylactic vaccines against lung cancer and HPV-related cancers respectively.

## Interesting Questions:
Q: What challenges did Dendreon face in developing its prostate cancer vaccine, and how have these been addressed by current mRNA immunotherapy developers?
A: Dendreon faced significant hurdles with high production costs and questions over cost-effectiveness. Current mRNA immunotherapy developers are making advances in targeting, delivering, and combining therapangs to overcome these challenges. By improving the technology's efficiency and effectiveness, they aim to create more affordable and accessible cancer treatments.

Q: How might the success of Moderna's mRNA immunotherapy for melanoma impact other types of cancers?
A: If successful, Moderna's mRNA immunotherapy could pave the way for similar therapies to be developed and tested against various cancer types. This would expand the potential market value and provide more treatment options for patients with different forms of cancer. Additionally, it may encourage further research into personalized medicine approaches tailored to individual tumor genetic signatures.

Q: What factors contribute to the valuation of mRNA immunotherapy companies like Moderna and BioNTech?
A: The valuation of mRNA immunotherapy companies is influenced by several factors, including their pipeline of vaccines and therapies, potential market size for each product, clinical trial results, intellectual property rights (such as patents), and the competitive landscape. Investors also consider the company's financial health, management team, and strategic partnerships when assessing its value. The success or failure of key products can significantly impact a company's valuation in this rapidly evolving field.

[Source Link](https://ft.com/content/d1d3c6b0-307a-485b-a48b-be635cdfd243)

